Adversity Level Determination In Nonclinical Toxicity Studies — A CRO Perspective

In this presentation, viewers will explore how to determine adversity levels during nonclinical toxicity studies, featuring case studies on overt toxicity, exaggerated pharmacology, and changes in toxicity markers in the context of other safety endpoints. This session will also guide viewers on interpreting data from toxicity studies to classify adverse versus non-adverse effects.

Led by Julie Forget, Director of Safety Assessment at Altasciences, this webinar leverages over 15 years of her expertise in preclinical research, ranging from discovery to IND/NDA-enabling studies. Altasciences offers comprehensive in vivo GLP and non-GLP preclinical evaluation services across multiple species, ensuring the generation of high-quality data for critical decision-making. With a commitment to scientific excellence, data integrity, and animal welfare, our services include IND-enabling and NDA-enabling toxicology, safety pharmacology, and laboratory studies that comply with global regulatory standards. Our seamless integration of preclinical and clinical services ensures a smooth transition from safety testing to first-in-human trials, helping expedite your drug development journey.